Objective-Allogeneic transplantation of human embryonic stem cell (hESC) derivatives has the potential to elicit the patient's immune response and lead to graft rejection. Although hESCs and their derivatives have been shown to have advantageous immune properties in vitro, such observations could not be determined experimentally in vivo because of ethical and technical constraints. However, the generation of humanized mice (hu-mice) harboring a human immune system has provided a tool to perform in vivo immunologic studies of human cells and tissues. Using this model, we sought to examine the therapeutic potential of hESC-derived endothelial cells, human embryonic fibroblasts, and cord blood-derived endothelial progenitor cells in a human immune system environment. Approach and Results-All cell types transplanted in hu-mice showed significantly reduced cell survival during the first 14 days post-transplantation compared with that observed in immunodeficient mice. During this period, no observable therapeutic effects were detected in the hindlimb ischemic mouse models. After this point, the cells demonstrated improved survival and contributed to a long-term improvement in blood perfusion. All cell types showed reduced therapeutic efficacy in hu-mice compared with NOD scid IL2 receptor gamma chain knockout mice. Interestingly, the eventual improvement in blood flow caused by the hESC-derived endothelial cells in hu-mice was not much lower than that observed in NOD scid IL2 receptor gamma chain knockout mice. Conclusions-These findings suggest that hESC derivatives may be considered a good source for cell therapy and that humice could be used as a preclinical in vivo animal model for the evaluation of therapeutic efficacy to predict the outcomes of human clinical trials. (Arterioscler Thromb Vasc Biol. 2013;33:2839-2849.)
H uman embryonic stem cells (hESCs) are capable of differentiating into almost all types of cells in the body. 1 For this reason, hESC derivatives are widely recognized as potential therapeutic agents for the treatment of various degenerative medical conditions. A growing number of translational studies has shown that hESC derivatives promote functional recovery by either secreting humoral factors or directly engrafting into the injured site. 2, 3 Thus, long-term survival of grafted hESC derivatives is key to promote stable, functional recovery at the injured site. 4 One of the factors affecting the in vivo survival of hESC derivatives is graft rejection, which occurs as a result of the activity of the recipient's immune system. 5, 6 hESCs express distinct major histocompatibility complex (MHC) antigens, the expression of which is elevated during differentiation. 7 For this reason, transplantation of MHC-mismatched hESC derivatives could activate the recipient's immune system through alloantigen recognition. 8 However, the immunogenicity of hESCs and their derivatives remains debatable, as they theoretically have beneficial immune properties because of their low expression of MHC class I molecules. 9 Several studies have been performed to examine the immunologic potential of hESCs, but because of ethical and technical constraints, such studies have only been performed in xenogeneic immunocompetent mice. 10, 11 Therefore, more extensive studies are required to fully predict the immunologic potential of hESCs in the human body. To do so, there is a genuine need for better preclinical models, which will ultimately diminish the risk for treated individuals.
For many years, mouse models have constituted useful in vivo tools for preclinical studies of various human therapies.
However, because of obvious physiological differences between mice and humans, such models do not necessarily represent outcomes in humans. 12 To provide more suitable in vivo models, mice have been humanized to recreate complex human physiological processes in small animals through the transplantation of functional human tissues into immunodeficient mice. 13 Different models of humanized mice (humice) have been generated for various types of biomedical research, such as studies of cancer, hematology, and HIV/ AIDS. [14] [15] [16] In particular, the technology for creating hu-mice harboring human immune systems has advanced in recent years and now permits the long-term engraftment of human hematopoietic stem cells and the production of hematopoietic lineages, including B and T cells. 13, 17 This type of hu-mouse model is thought to provide a useful preclinical model to test the safety and efficacy of hESC-based regenerative medicine. 18 The potential therapeutic application of hESC-derived endothelial cells (hESC-ECs) and cord blood-derived endothelial progenitor cells (CB-EPCs) has been suggested because of their ability to induce neovascularization under ischemic conditions. 2, [19] [20] [21] These studies have been largely performed in immunodeficient mice, which bypasses the immunologic defense mechanisms that could reduce overall therapeutic efficacy in the human body.
In this study, we evaluated the therapeutic efficacy of human embryonic fibroblasts (hEFs), CB-EPCs, and hESC-ECs to promote neovascularization in hindlimb ischemia using mice with different immune competencies. Graft rejection was observed when all cell types were transplanted into xenogeneic immunocompetent mice 6 days post-transplantation, and this transfer therefore demonstrated no therapeutic effects. In immunodeficient mice, we observed prolonged survival and a significant improvement in blood perfusion in the ischemic region as early as 6 days post-transplantation. The survival of all cell types was limited in hu-mice during the first 14 days post-transplantation, and there was no observable functional improvement. However, after this point, the cells demonstrated improved survival and led to a stable increase in blood perfusion for 2 weeks. Surprisingly, the eventual improvement in blood flow caused by hESC-ECs in hu-mice was not much different from that observed in immunodeficient mice. Our findings suggest that hu-mice could provide a valuable in vivo preclinical tool to predict the likelihood of functional improvement in humans transplanted with hESC derivatives.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Confirmation of a Reconstituted Human Immune System in Immunodeficient Mice
To create an in vivo human immune system in the mouse, we generated hu-mice according to the schematic shown in Figure 1A . The distribution of human immune cells in the peripheral blood of NOD scid IL2 receptor gamma chain knockout (NSG) mice was analyzed by measuring CD45+ cells every 4 weeks postinjection (4 weeks: n=72; 8 weeks: n=67; 12 weeks: n=52; and 16 weeks: n=25; Figure 1B) . After a 12-week generation process, ≈72% (n=52/72) existed with the exception of formerly used hu-mice (n=11), and ≈31.92% cells were shown to be CD45+ by fluorescence-activated cell sorting analysis of the peripheral blood ( Figure 1B ). Only a small proportion of T cells (CD3) was detected during the first 8 weeks after generation, but the T-cell frequency gradually increased to ≈19.7% and 32.6% by 12 and 16 weeks, respectively ( Figure 1C ). In addition, we analyzed the reconstitution of human T (CD3), B (CD19), NK (CD56), and myeloid (CD33) cells within the CD45+ cell population in the bone marrow, spleen, and liver of NSG mice at 16 weeks post-transplantation with hUCB-CD34+ cells ( Figure 1D and 1E; n=14). According to the fluorescence-activated cell sorting analysis of the human immune cell populations within the 3 organs, we confirmed that hu-mice possessing a human immune system were generated successfully from NSG mice.
Survival of hEFs, CB-EPCs, and hESC-ECs in Mouse Strains With Different Immune Competencies
Before cell transplantation experiments, we have analyzed the cellular characterization of hESC-EC ( Figure I Especially, hESC-ECs were generated from a karyotypically normal H9 cell line, according to the methods listed in our previous studies. 2, 3, 22 In addition, we identified for sorted hES-ECs at passage 3 before cell transplantation ( Figure IC -IE in the online-only Data Supplement). To analyze cell survival, all cell types were transplanted into immunocompetent mice (C57BL/6, n=7), immune-deficient mice (NSG, n=7), and mice harboring a functional human immune system (hu-mice, n=8). For the analysis of noninvasive cell survival, all cell types were prelabeled with DiD-cy5.5, and their survival was measured by their signal intensity using Xenogen ( Figure II in the online-only Data Supplement). As expected, the transplantation of all cell types in C57BL/6 mice resulted in limited cell survival ( Figure 2A ); each cell type showed dramatic cell death, as the signal intensities of these cells decreased significantly 3 days after transplantation (hEFs=33.37±3.35%, CB-EPCs=21.28±2.53%, and hESC-ECs=35.31±3.84%; Figure 2D ). Complete graft rejection of all cell types was observed 7 days after transplantation, as the signal intensities dropped to an undetectable level (hEFs=2.31±0.73%, CB-EPCs=0.87±0.45%, and hESC-ECs=5.73±2.33%; Figure 2D ). In contrast, when the cells were transplanted into NSG mice, we observed prolonged cell survival ( Figure 2B ); compared with C57BL/6 mice, significantly more viable hEFs and hESC-ECs were detected, as shown by the gradual loss of signal intensity during the first 14 days post-transplantation (hEFs=80.28±3.91% and hESC-ECs=77.71±2.45%; Figure 2E ). The majority of viable cells remained alive, and both hEFs and hESC-ECs maintained ≈57% signal intensity when measured on day 28 post-transplantation ( Figure 2B and 2E). The survival of the CB-EPCs was also prolonged compared with that observed in C57BL/6 mice ( Figure 2B , blue arrowheads). However, when compared with the hEFs and hESC-ECs in NSG mice, the survival of the CB-EPCs was lower at each measured interval (≈71% and ≈45% at 14 and 28 days post-transplantation, respectively; Figure 2E ). Each cell type transplanted into hu-mice demonstrated similar survival patterns ( Figure 2C) , and cells experienced a dramatic level of cell death during the first 14 days post-transplantation, with CB-EPCs demonstrating the most dramatic loss of viability (hEFs=35.33±5.11%, CB-EPCs=23.70±9.73%, and hESC-ECs=47.33±3.57%; Figure 2F ). The cells continued to lose viability, albeit at a reduced rate, as measured by recording the signal intensity on day 28 post-transplantation ( Figure 2F ). The percentage of remaining viable hESC-ECs on day 28 was ≈35%, which indicated superior survival when compared with hEFs (≈15%) and CB-EPCs (≈5%; Figure 2F ).
Different Immunogenicities of hEFs, CB-EPCs, and hESC-ECs to the Immune Cells of hu-Mice
The innate production of interferon-γ (IFN-γ) is the first event to occur after the immune detection of pathogens. 23 To examine whether the impaired survival of the 3 cell types examined in hu-mice was attributable to an elevated production of IFN-γ, we first cocultured each cell type with hu-mice splenocytes and measured IFN-γ production on days 1, 3, and 5. No significant level of IFN-γ was detected on day 1 in each coculture group compared with the control splenocyte culture ( Figure 3A ). However, IFN-γ production by splenocytes cocultured with hEFs significantly increased compared with the control group on day 3 (2.0-fold increase; Figure 3A ).
Splenocytes cocultured with CB-EPCs and hESC-ECs also exhibited a significant elevation in IFN-γ production compared with the control group (1.3-and 1.2-fold increases, respectively), but this elevation was less dramatic than that observed in splenocytes cocultured with hEFs ( Figure 3A ). On day 5, splenocytes cocultured with hEFs and CB-EPCs demonstrated 2.9-and 1.6-fold increases in IFN-γ production, respectively, compared with the control group ( Figure 3A) . Interestingly, IFN-γ production by splenocytes cocultured with hESC-ECs was not significantly different from that of the control culture ( Figure 3A ). After that, T cells (CD4+ and CD8+ cells) were confirmed by intracellular IFN-γ staining as a major source of IFN-γ within the splenocyte ( Figure VIII in the online-only Data Supplement) and IFN-γ production by CD3 T cells cocultured with hEFs significantly increased compared with cells cocultured with CB-EPCs and hESC-ECs group on day 5 ( Figure 3B ). Next, we analyzed the expression level of MHC class I (human leukocyte antigen [HLA]-ABC) and class II (HLA-DR) molecules on each cell type by fluorescence-activated cell sorting and found that hEFs expressed MHC class I molecules (mean fluorescence intensity [MFI], 414.18±15.59) at a level that was significantly higher than that observed for CB-EPCs and hESC-ECs (MFI, 67.95±2.58 and 69.2±3.52, respectively; Figure 3C ). As expected, all cell types were devoid of MHC class II molecule expression (hEFs: MFI, 4.19±0.21; CB-EPCs: MFI, 3.84±0.58; and hESC-ECs: MFI, 4.21±0.1), as these molecules are only expressed on antigen-presenting cells, such as B cells, macrophages, and dendritic cells. 24, 25 Moreover, to confirm the relationship between MHC class I molecule expression and immunogenicity, we have established lentiviral β2 microglobulin (β2M)-specific shRNA expression system in hEF cells for the MHC class I-suppressed situation. hEF cells stably expressing β2M-specific shRNA reduced β2M surface expression by ≈70% in culture compared with the expression rate in control virus-transduced cells ( Figure IXA in the online-only Data Supplement). Also from the result of IFN-γ secretion assay, hu-mice splenocytes were incubated with several target cells, such as hEF cells, control lentivirus-transduced hEF cells (hEF-shControl), and β2M-specific shRNA-expressed hEF cells (hEF-shβ2M). In the presence of hEF cells presenting normal levels of MHC class I expression, hu-mice splenocytes produced higher IFN-γ levels compared with the level when incubated with MHC class I-suppressed cells ( Figure IXB in the online-only Data Supplement). These results suggest that there is relationship between MHC class I expression level and immunogenicity in hu-mice. From these observations, we hypothesized that the different survivabilities of each cell type may be related to the induction of the cellular immune response (IFN-γ secretion), and we concluded that the low immunogenicity of the allogenic hESC derivatives was consistent with their low level of MHC class I expression.
Comparison of Therapeutic Efficacies for Improving Blood Flow in Models of Hindlimb Ischemia in NSG and hu-Mice
Translational studies of CB-EPCs and hESC-ECs have shown their potential to be used in cellular therapies to treat various forms of ischemic diseases. 2, 21, 26, 27 However, these studies could not predict accurate therapeutic outcomes in humans, as these observations were based in immunodeficient mouse models. In an attempt to provide a more reliable prediction, we assessed the therapeutic efficacy of CB-EPCs and hESC-ECs after transplantation of these cells into hu-mice after surgically creating hindlimb ischemia ( Figure 4A ). Before injecting the cells into the ischemic region, blood perfusion was measured at day 0 to verify that the surgery had been successful in generating hindlimb ischemia ( Figure 4B-4F ). NSG mice injected with cells into the ischemic region were used as controls, and we compared functional recovery by examining blood flow in the ischemic region using a Laser Doppler A, Analysis of IFN-γ production in hu-mice splenocytes after a 1-way mixed lymphocyte reaction by ELISA. Each cell type (2×10 5 cells) was treated with mitomycin C (25 mg/mL) and cocultured with 2×10 5 hu-mice splenocytes. IFN-γ production was measured on days 1, 3, and 5. A gradual increase in IFN-γ production was observed after 5 days for the human embryonic fibroblast (hEF) and cord blood-derived endothelial progenitor cell (CB-EPC) coculture groups compared with the control splenocyte culture. About the human embryonic stem cell-derived endothelial cell (hESC-EC) coculture group, a slight increase in IFN-γ production was observed on day 3, but there was no significant difference in production on day 5. B, Each cell type (2×10 5 cells) was treated with mitomycin C (25 mg/mL) and cocultured with 2×10 5 CD3+ T-cell populations of hu-mice splenocytes. IFN-γ production was measured on days 5. IFN-γ production by CD3+ T cell was measured by ELISA. C, Analysis of the expression levels of the human MHC molecules (human leukocyte antigen [HLA]-ABC and HLA-DR) on the cell surface of hEFs, CB-EPCs, and hESC-ECs using fluorescence-activated cell sorting. Data are representative as the mean fluorescence intensity±SD. December 2013 perfusion imaging system. hEFs were ineffective at improving blood flow when transplanted into the ischemic region of humice compared with NSG mice ( Figure 4B ). In NSG mice, a significant improvement in blood flow was observed 14 days post-transplantation (≈23%), but no further improvements were observed when blood flow was measured again on day 28 (≈29%; Figure 4C ). In hu-mice, no significant improvement in blood flow was observed during the course of treatment ( Figure 4C ), which are similar to the result of phosphate buffered saline-only treated group without cells ( Figure VI in the online-only Data Supplement). CB-EPCs were shown to be more effective at recovering restricted blood flow in the ischemic regions of NSG and hu-mice. We observed a noticeable increase in blood flow at 7 days post-transplantation (≈12%) when CB-EPCs were transplanted into NSG mice ( Figure 4D ), and this blood flow was shown to increase further at a steady rate for an additional 2 weeks (from ≈12% to ≈62% between 7 and 21 days post-transplantation; Figure 4E ) before reaching a plateau at day 28 post-transplantation (≈67%; Figure 4E ). A reduction in the therapeutic efficacy of CB-EPCs was observed when these cells were transplanted into the ischemic region of hu-mice. In these animals, the blood flow remained unchanged at 7 days post-transplantation but increased up to ≈13% by 14 days post-transplantation ( Figure 4E ). This improvement was comparable with that observed in NSG mice at 7 days post-transplantation with CB-EPCs, indicating a delayed therapeutic effect in the hu-mice (NSG≈12% of 7 days and hu-mice≈13% of 14 days; Figure 4E ). In addition, the improved blood flow observed at 14 days post-transplantation in hu-mice was significantly less than that detected in NSG mice at the same time point (NSG≈33% and hu-mice≈13%; Figure 4E ). CB-EPCs continued to contribute to blood flow improvement in hu-mice until 28 days post-transplantation, but this improvement was significantly less than that observed in NSG mice (NSG≈67% and hu-mice≈42%; Figure 4E ).
Next, we compared the therapeutic efficacy of hESC-ECs using the same mouse models ( Figure 4F ). Remarkably, we observed a ≈16% increase in blood flow at 7 days posttransplantation of hESC-ECs into NSG mice, which was significantly greater than that observed after hEF and CB-EPC transplantation ( Figure 4G ). From this time on, blood flow increased sharply at a steady rate and achieved ≈73% limb perfusion by 21 days post-transplantation before reaching a plateau with ≈80% limb perfusion on day 28 post-transplantation ( Figure 4G ). In comparison, the therapeutic effects of hESC-ECs transplanted in hu-mice were less dramatic; the improvement in blood flow was gradual during the initial 14-day period after transplantation (≈16%; Figure 4G ) but was followed by a sharp increase in blood flow until day 28 post-transplantation (≈70%; Figure 4G ). Interestingly, in line with the analysis of the therapeutic effects of CB-EPCs in both mouse models, the percentages of limb perfusion at each measured interval in the hu-mice were less than those observed in NSG mice ( Figure 4G ). However, unlike CB-EPCs, the eventual improvement in blood perfusion mediated by hESC-ECs on day 28 post-transplantation was relatively high in hu-mice compared with NSG mice ( Figure 4G ).
hESC-EC Transplantation Improved Tissue Regeneration in Ischemic Limbs
The histological examination of muscle degeneration and fibrosis involved harvesting ischemic limbs at 4 weeks posttransplantation ( Figure 5A) , and hematoxylin and eosin staining of the hEF-transplanted limbs demonstrated massive muscle degeneration and the presence of abnormal structures. In contrast, muscles from the hESC-EC and CB-EPC transplantation groups had degenerated only slightly, especially those in the hESC-EC group, which exhibited near-normal structures ( Figure 5A, first row) . Furthermore, Masson's trichrome staining of the hEF group showed serious muscle fibrosis, whereas the muscle tissue damage in the hESC-EC group was markedly attenuated ( Figure 5A ; second row). Arteriole and capillary enrichment was analyzed by performing mouse endothelial cell antigen, smooth muscle actin, and platelet endothelial cell adhesion molecule (PECAM) stains on the harvested tissues and using normal limb muscles as a control ( Figure 5A , third, fourth, and fifth rows, respectively). These immunohistochemical examinations and the quantification of (mouse endothelial cell antigen)-stained vessels revealed that the implantation of hESC-ECs inhibited vessel damage after ischemia (35.85±9.73/mm 2 ) when compared with the implantation of CB-EPCs (31.57±7.27/mm 2 ; Figure 5B ). In addition, immunohistochemical staining for smooth muscle actin and the quantification of arteriole density demonstrated significantly enhanced arteriole formation mediated by hESC-ECs (23.57±13.53/mm 2 ) compared with CB-EPCs (14.28±7.22/ mm 2 ; Figure 5C ). Staining for PECAM and the quantification of capillary density also revealed dramatic improvements in mice treated with hESC-ECs (118.14±65.95/mm 2 ) compared with those treated with CB-EPCs (86.71±49.32/mm 2 ; Figure 5D ). These quantification results revealed that transplantation of hESC-ECs dramatically enhanced smooth muscle actin-positive arteriole formation and PECAM-positive density in ischemic regions compared with the transplantation of hEFs or CB-EPCs.
Next, to investigate the engraftment of transplanted Dillabeled hESC-ECs, we fluorescently stained ischemic limb tissues. Staining with BS-1 lectin revealed that transplanted hESC-ECs could be detected in capillaries near muscle tissues in ischemic regions and that these cells had been incorporated into the vessels between muscle tissues ( Figure 5E ; white arrowhead). This result indicated that neovessels induced by hESC-EC transplantation were functional blood vessels that contributed to blood perfusion. PECAM immunostaining showed that Dil-and PECAM-positive cells were present ( Figure 5F ), and the capillary networks comprised PECAM-positive transplanted cells ( Figure 5F , white arrowhead) and PECAM-positive nontransplanted cells ( Figure 5F , black arrowhead) in ischemic muscles. Moreover, mouse-specific smooth muscle actin and human-specific human nuclear antigen staining confirmed the presence of hybrid blood vessels composed of transplanted hESC-ECs ( Figure 5G and 5I, white arrowhead) and mouse ECs ( Figure 5G , black arrowhead). Collectively, hESC-ECs survived after transplantation, engrafted into mouse tissue, and induced the formation of vascular networks in ischemic muscles ( Figure 5G and 5I; Movie I in the online-only Data Supplement). These results highlight the therapeutic contribution of hESC-ECs to neovascularization in hu-mice.
Discussion
The therapeutic efficacy of allogeneic hESC derivatives in humans remains largely elusive, partly because of the potential for graft rejection by the recipient's immune system. 6 These types of therapy carry significant importance, as Food and Drug Administration-approved human clinical trials of hESC derivatives are currently underway (www.advancedcell. com). It has been accepted widely that the administration of immunosuppressive drugs can inhibit the complications associated with the immunologic rejection of hESC derivatives post-transplantation. 28 However, this practice is not ideal, as prolonged use of such drugs can leave patients vulnerable to opportunistic infections. 29 Moreover, it has been reported that long-term use of these drugs may not be required because of (1) the low expression levels of MHC class I molecules on hESCs and their derivatives, which render them less susceptible to immune attack 9 and (2) the fact that short-term use of immunosuppressants at the onset of treatment is sufficient to induce long-term survival and engraftment of transplanted hESC derivatives. 30 Previous studies have attempted to determine the immunologic potential of hESCs and their derivatives in xenogeneic settings, but because of differences in physiological and biological processes between humans and mice, outcomes of these studies have not necessarily provided a true representation of human outcomes. 10, 11 Therefore, the main aim of this study was to evaluate the influence of a functional human immune system on the therapeutic efficacy of hESC-ECs using hu-mice as an in vivo tool.
All cell types demonstrated dramatically reduced viability during the first 14 days post-transplantation in hu-mice compared with NSG mice (Figure 2E and 2F ). Because the possession of a human immune system is the only difference between these 2 mouse models, this distinction may account for the differences in the survival of the transplanted cell types. To understand the major cell population related to the immune response in hu-mice, we performed IFN-γ secretion assay with hu-mice splenocytes. In this experiment, IFN-γ was detected in the several kinds of immune cells and we found that CD8+ T cell was the major cell population secreting IFN-γ within a coculture ( Figure VIII in the online-only Data Supplement). However, there was no detection of IFN-γ-secreting CD56+ NK cell and CD68+ MØ. Although the immune response mechanisms were not specifically evaluated in the hu-mice, transplanted cells seemed to be reduced by CD8+ T cell response. As previously reported, short-term inhibition of the T-cell-mediated immune response is important for engraftment of hESCs, 30 and T-cellspecific immunosuppression is known to significantly prolong xenogenic hESC survival in immunocompetent mice. 11 In addition, NK cells are known to uniquely target cells with low expression of MHC class I molecules 31 ; however, only T-celldeficient animals fail to reject hESCs, 32 and human NK cells do not recognize effectively the hESCs in vitro. 33 From these in vitro results, it seems that human NK cells in hu-mice are not major immune responsor to hESC transplantations, and that the naturally low expression level of MHC class I molecules on hESC derivatives may result in a minimal host cellular immune response. In this study, we observed that the cell death of hEFs and CB-EPCs in hu-mice 14 days post-transplantation was significantly greater than that of hESC-ECs ( Figure 2F ). As hEFs and CB-EPCs stimulated 2.9-and 1.6-fold increases in IFN-γ production by splenocytes from hu-mice, respectively, compared with control hu-mice splenocytes ( Figure 3A) , we hypothesized that the cellular immune response (in terms of IFN-γ production) may be directly linked with the different survivabilities of transferred hEFs and CB-EPCs. Therefore, it is plausible that the increased IFN-γ production observed after the transplantation of hEFs and CB-EPCs into hu-mice may have activated a cell-mediated immune response against the transplanted cell types.
As expected, we observed no significant functional improvement during the period in which the CB-EPCs and hESC-ECs underwent dramatic reductions in viability ( Figure 4E and 4G) . However, when cell survival was more stable, we were able to observe a stable increase in blood perfusion for the CB-EPCs and hESC-ECs ( Figure 4E and 4G) . Strikingly, although the therapeutic effects of hESC-ECs were observed at a delayed time point, the eventual improvement in blood perfusion by 28 days post-transplantation was similar to that observed in NSG mice ( Figure 4G ). This phenomenon was not observed with CB-EPCs, as the eventual improvement in blood perfusion in hu-mice was significantly less than that observed in NSG mice ( Figure 4E ). However, unlike NSG mice, improvement of blood flow at day 14 was not as notable in hu-mice when transplanted with all 3 cell types. Figure 2F reveals that the survivals of injected cells were affected by immune rejection of hu-mice compared with the NSG mice ( Figure 2E ) for 14 days, which gave rise to differences in therapeutic effects. Basically, hESC-ECs showed higher survival than CB-EPCs or hEFs in hu-mice ( Figure 2E ), which was detected in the ischemic region at day 28 ( Figure 5I ). Unfortunately, we could not evaluate the remaining cell population at the end point post cell transplantation. However, to provide the therapeutic property of hESC-ECs for significant improvement of blood flow after 14 days post cell transplantation, we performed ELISA to measure the secretions of humoral angiogenic factors as a paracrine ability of cells. As a result, we found that hESC-ECs secreted higher amounts of vascular endothelial growth factor and angiopoietin-1 in comparison with hEFs or CB-EPCs ( Figure VII in the online-only Data Supplement). Such survival property and paracrine effects of hESC-ECs resultantly contributed to the recovery of ischemia in hu-mice at end point, which was similar to that of immunodeficient NSG mice. In addition, histological analysis of hindlimb ischemic regions demonstrated that hESC-ECs were more efficient at attenuating muscle degeneration and fibrosis compared with CB-EPCs ( Figure 5A ). Functional engraftment of hESC-ECs was also observed in the ischemic region of hu-mice, indicating that hESC-ECs are capable of recovering blood perfusion by directly incorporating into the injured area in the presence of a human immune system. These findings suggest that the therapeutic efficacy of CB-EPCs is significantly reduced by the presence of a human immune system.
Based on the data presented in this study, it is plausible to suggest that the human immune system reduces the efficacy of hESC-ECs to restore functionality in diseased conditions rather than rejecting the graft entirely, as previously thought. We also think that improved survival, and therefore engraftment, could be achieved if HLA matching is available for patients receiving hESC treatment. 34 Based on the HLA type, it has been estimated that ≈170 hESC lines would be required to provide 1 hESC line carrying only a single HLA mismatch to 80% of the patients in Japan. 35 Therefore, the generation of patient-specific stem cell lines has been proposed in the form of induced pluripotent stem cells to avoid complications associated with immunogenicity. 36 Although induced pluripotent stem cells are reprogrammed from a patient's own somatic cells, 1 study demonstrated graft rejection of mouse induced pluripotent stem cells, which has prompted more extensive studies on the immunologic potential of induced pluripotent stem cells for human clinical application. 37 Therefore, the establishment of a hESC bank containing cell lines with diverse MHC expression presents a potential solution to the need for safe and efficient cell therapy treatments. 38 In conclusion, the current study successfully mimicked the human immune system in mice through the transplantation of hematopoietic stem cells and also examined the immunogenic potential of hESC-ECs. The therapeutic efficacy of the hESC-ECs was reduced, but compared with hEFs and CB-EPCs, these cells were shown to be less susceptible to immune responses and possess somewhat beneficial immune properties. These results suggest that the application of hESC-ECs for treatment of ischemic diseases could be achieved with minimal use of immunosuppressive drugs, and that the integration of hu-mice for the validation of hESC derivatives should promote the application of these types of cellular therapy.
